Sangamo BioSciences' CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Sangamo BioSciences (SGMO)

Presentation at Bank of America Merrill Lynch 2012 Health Care Conference

May 16, 2012 5:20 p.m. ET

Executives

Edward Lanphier - President and CEO

Analysts



Rachel McMinn - Bank of America Merrill Lynch

Presentation

Rachel McMinn - Bank of America Merrill Lynch

Compare to:
Previous Statements by SGMO
» Sangamo's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Sangamo BioSciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Sangamo BioSciences' CEO Presents at the 30th Annual J.P. Morgan Healthcare Conference (Transcript)
» Sangamo BioSciences at Lazard Capital Markets 8th Annual Healthcare Conference Call Transcript

My name’s Rachel McMinn. I’m one of the biotech analysts here at Bank of America Merrill Lynch. It’s my pleasure to introduce our next speaker. The company is Sangamo BioSciences, and our speaker is President and CEO Ed Lanphier. Thanks so much.

Edward Lanphier

Thank you Rachel, and thanks for including us in this year’s conference. It’s a pleasure to be here. My presentation will continue forward looking statements, and I’d refer you to our forms 10-K, 10-Q, filed with the SEC.

Starting at 30,000 feet, the single fact that differentiates Sangamo from every company at this meeting, every company in biotech, is our core technology, our ability to engineer a naturally occurring class of proteins that bind DNA. And these are called zinc finger proteins.

They’re actually the most common, the most abundant, class of DNA binding proteins found on our planet, and the reason being is evolution found these to be very engineerable, very manipulable, in that they can bind to three sequences of DNA, three base pairs of DNA, and then linking these together kind of like Legos, could build proteins that could recognize longer and more specific sequences of DNA.

1 2 3 4 Next › Last »